Search results
This Technology Company Is Being Acquired at a Shocking 207% Premium -- and These 2 Stocks Could Be...
Motley Fool via Yahoo Finance· 16 hours agoNot only is the company losing money hand over fist, but its revenue is actually declining, mainly...
Two new malaria vaccines are being rolled out across Africa: How they work and what they promise
Medical Xpress· 7 hours agoThis year two revolutionary malaria vaccines are being rolled out across the continent. Nadine...
Peripheral Neuropathy Market is Expected to Hit USD 7.95 Billion by 2031
Digital Journal· 4 days agoAccording to SNS Insider, Peripheral Neuropathy Market is projected to reach USD 7.95 Billion by...
Asthma Attack: Allergies, Rising Costs Impacting Patients
WebMD· 6 days agoAcross the U.S., warmer days have beckoned an earlier spring, and with that, an earlier pollen season and worse seasonal allergies. Pair that with an ongoing respiratory virus season – particularly ...
Nelson Peltz Got Crushed by Disney. Can He Recover?
The Wall Street Journal· 7 days agoNelson Peltz’s proxy fight at Disney had the potential to help turn around his hedge fund after a tumultuous stretch. Instead, the activist investor’s...
23andMe CEO plans to take company private
MedTech Dive via Yahoo Finance· 6 days agoWojcicki's proposal as the new most likely outcome which should be welcomed by investors.” 23andMe has faced financial pressure as sales of DNA tests...
Scientists Discover New Antibiotic Class Effective Against Drug-Resistant Bacteria
SciTechDaily· 1 day agoResearchers at Uppsala University have discovered a new class of antibiotics with potent activity...
A Look at Trabectedin Monotherapy for Recurrent Ovarian Cancer
MedPage Today· 6 days agoTreatment with trabectedin monotherapy did not extend median overall survival (OS) in a prospective,...
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed...
WJTV Jackson· 7 days agoContinuous Kesimpta® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve people living with relapsing multiple sclerosis (RMS) in an analysis ...
Middlesex chief executive: 'Why could Lord's not become like the San Siro in Milan?'
ESPN· 2 days agoMiddlesex are weighing up their options for a future away from Lord's, their county home for the...
